trending Market Intelligence /marketintelligence/en/news-insights/trending/e3MFcWzfumMmtaMs6nd9ag2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Merck KGaA, Promega enter CRISPR licensing deal

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Merck KGaA, Promega enter CRISPR licensing deal

MERCK KGaA has entered a license agreement to provide Promega Corp. access to its intellectual property relating to CRISPR gene-editing technology to create research products and services.

Madison, Wis.-based Promega plans to use the technology to develop CRISPR-edited cell lines, which play a major role in determining the efficacy and toxicity of potential treatments during the drug development cycle. Financial details of the agreement were not disclosed.

CRISPR technology uses a derived protein or enzyme system to cut and then revise, remove or replace certain DNA sequences.

The Cas9 protein is most commonly used in CRISPR gene editing. It was discovered by Jennifer Doudna of the University of California, Berkeley, and Emmanuelle Charpentier of the University of Vienna in 2011. The technology deploys RNA to guide the Cas9 enzyme to a specific target DNA sequence, which the enzyme then cuts. Following that, the cell can be altered and repaired.

Merck holds 22 patents worldwide related to CRISPR methods and composition, including the CRISPR Cas9 for use in genetic integration in mammalian cells.

Earlier in November, Merck entered a license agreement providing Evotec SE access to its CRISPR technology.

Privately held Promega manufactures reagents and instrumentations to help life scientists offering products in the areas of cell biology.